(HealthDay News) — Many U.S. patients with breast cancer still get radiation therapy for much longer than they need to, according to research published online December 10 in the Journal of the American Medical Association.
The analysis of data indicates that two-thirds of breast cancer patients who’ve had breast-conserving surgery undergo six to seven weeks of radiation therapy. However, multiple studies suggest that an alternative course of three weeks of higher-dose radiation – hypofractionated whole breast radiation – is just as effective, more convenient, and less expensive than longer, conventional radiation therapy. The newer type of radiation therapy is supported by four studies and practice guidelines from the American Society for Radiation Oncology, the researchers note.
The researchers found that in 2013, only 34.5% of early-stage breast cancer patients aged >50 received the shorter-course hypofractionated therapy. Among younger women and those with more advanced cancers, 21.2% received hypofractionated therapy in 2013, compared with 8.1% in 2008. However, use of the newer, shorter-course therapy has accelerated much more in Canada. In that country, 71% of early-stage breast cancer patients were already receiving hypofractionated radiation therapy by 2008.
The researchers also found that the use of hypofractionated radiation therapy reduced insurers’ costs in the first year after breast cancer diagnosis by 10%. The switch to the shorter-course therapy had little effect on patients’ out-of-pocket costs, but it did reduce the time patients needed to be away from work and home, which means they did get economic and quality-of-life benefits.